Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 28;35(5):695-708.
doi: 10.1002/sim.6746. Epub 2015 Oct 4.

Bayesian approach for assessing non-inferiority in a three-arm trial with pre-specified margin

Affiliations

Bayesian approach for assessing non-inferiority in a three-arm trial with pre-specified margin

Samiran Ghosh et al. Stat Med. .

Abstract

Non-inferiority trials are becoming increasingly popular for comparative effectiveness research. However, inclusion of the placebo arm, whenever possible, gives rise to a three-arm trial which has lesser burdensome assumptions than a standard two-arm non-inferiority trial. Most of the past developments in a three-arm trial consider defining a pre-specified fraction of unknown effect size of reference drug, that is, without directly specifying a fixed non-inferiority margin. However, in some recent developments, a more direct approach is being considered with pre-specified fixed margin albeit in the frequentist setup. Bayesian paradigm provides a natural path to integrate historical and current trials' information via sequential learning. In this paper, we propose a Bayesian approach for simultaneous testing of non-inferiority and assay sensitivity in a three-arm trial with normal responses. For the experimental arm, in absence of historical information, non-informative priors are assumed under two situations, namely when (i) variance is known and (ii) variance is unknown. A Bayesian decision criteria is derived and compared with the frequentist method using simulation studies. Finally, several published clinical trial examples are reanalyzed to demonstrate the benefit of the proposed procedure.

Keywords: Bayesian Method; Jeffreys' prior; Markov chain Monte Carlo; assay sensitivity; non-inferiority margin.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Density plot of NI margin over 10000 simulations for two different situations, evaluating the effect of historical trial over the width of NI margin.

Similar articles

Cited by

References

    1. D’Agostino RB, Massaro JM, and Sullivan LM. Noninferiority trials: Design concepts and issues-the encounters of academic consultants in statistics. Statistics in Medicine, 22(2):169–186, 2003. - PubMed
    1. ICHE9. ICH Harmonised Tripartite Guideline. Statistical Principles for Clinical Trials. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009.
    1. ICHE10. ICH Harmonised Tripartite Guideline. Choice of Control Group and Related Issues in Clinical Trials. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009.
    1. FDA. Food and Drug Administration Guidance for Industry Noninferiority Clinical Trials., 2010.
    1. EMA. Guideline on the choice of the noninferiority margin (Doc. Ref. EMEA/CPMP/EWP/215)., 2005.

Publication types

MeSH terms

LinkOut - more resources